Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant t
- PDF / 667,990 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 20 Downloads / 203 Views
ORIGINAL ARTICLE
Comparison of thyroid hormone withdrawal and recombinant human thyroid‑stimulating hormone administration for adjuvant therapy in patients with intermediate‑ to high‑risk differentiated thyroid cancer Yusuke Iizuka1 · Tomohiro Katagiri1 · Kengo Ogura1 · Minoru Inoue1 · Kiyonao Nakamura1 · Takashi Mizowaki1 Received: 7 May 2020 / Accepted: 30 June 2020 © The Japanese Society of Nuclear Medicine 2020
Abstract Objective To compare the clinical outcome in patients who received adjuvant therapy with radioactive iodine (RAI) using different preparation methods, namely, thyroid hormone withdrawal (THW) and recombinant human thyroid-stimulating hormone (rhTSH), after undergoing thyroidectomy for intermediate- to high-risk differentiated thyroid carcinoma (DTC) according to the American Thyroid Association criteria. Methods Between May 2012 and October 2018, 136 patients who underwent adjuvant therapy with high-dose (3700 MBq) RAI for DTC without any metastatic lesions or macroscopic residual lesions after surgical resection were retrospectively selected. Patients were excluded if distant metastasis was confirmed during adjuvant therapy or if the outcome could not be confirmed; thus, 112 patients were finally evaluated. Patients underwent either a 3-week I restriction with thyroxine withdrawal or a 2-week I restriction with rhTSH administration. The serum thyroglobulin (Tg) concentration was measured, and 131 I scintigraphy (370 MBq) was performed 6–12 months after adjuvant therapy. The definition of the initial achievement of adjuvant therapy was the disappearance of the uptake of 131I at the thyroid bed and serum Tg concentration
Data Loading...
